Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company in 2022
|
| gptkbp:awards |
Awards for innovation in healthcare
|
| gptkbp:CEO |
Gal_Cohen
|
| gptkbp:clinicalTrials |
Ongoing clinical research studies
Phase 3 trials for NexoBrid |
| gptkbp:collaborations |
Collaboration with universities for research
|
| gptkbp:employees |
Over 100 employees
|
| gptkbp:financials |
Publicly traded financial reports
|
| gptkbp:focus |
wound care
|
| gptkbp:founded |
2001
|
| gptkbp:headquarters |
Yavne, Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
MediWound Ltd.
|
| gptkbp:investmentFocus |
Institutional investors
|
| gptkbp:market |
global market for wound care
|
| gptkbp:mission |
To improve patient outcomes in wound care.
|
| gptkbp:partnerships |
MediWound_Ltd._and_the_U.S._Army
|
| gptkbp:patentCitation |
Multiple patents in wound care technology
|
| gptkbp:products |
gptkb:NexoBrid
Innovative product development in wound care EscharEx |
| gptkbp:regulatoryCompliance |
FDA_approval_for_NexoBrid
|
| gptkbp:researchFocus |
biologics for wound healing
|
| gptkbp:stockSymbol |
MDWD
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.mediwound.com
|